Logotype for 908 Devices Inc

908 Devices (MASS) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for 908 Devices Inc

Q1 2026 earnings summary

6 May, 2026

Executive summary

  • Q1 2026 revenue reached $13.4 million, up 14% year-over-year, driven by growth in both Mass Spec and FTIR segments and strong U.S. state and local sales.

  • Achieved significant strategic transformation in 2025, including positive adjusted EBITDA in Q4 and an installed base exceeding 3,900 devices by March 2026.

  • Acquisition of NIRLAB AG announced/completed in May 2026, expanding drug detection capabilities, recurring revenue streams, and international reach.

  • Integration of RedWave FTIR portfolio and successful product launches, such as VipIR, contributed to sustained growth and innovation.

  • Law enforcement and corrections markets remain key, with notable impact from initiatives like Virginia's Operation Free and regulatory changes.

Financial highlights

  • Q1 2026 product revenue was $10.7 million, up 26% year-over-year, with recurring revenue at $4.0 million (30% of total), and service/contract revenue at $2.6 million.

  • Gross profit was $6.9 million (GAAP, 51–52% margin), with adjusted gross margin at 57%; adjusted EBITDA loss narrowed to $2.5 million from $4.6 million year-over-year.

  • Net loss from continuing operations was $12.0 million, impacted by non-cash contingent consideration charges.

  • Cash, cash equivalents, and marketable securities totaled $111.7 million as of March 31, 2026, with no debt.

  • Operating expenses increased to $19.8 million, mainly due to contingent consideration related to RedWave.

Outlook and guidance

  • 2026 revenue guidance raised to $67–$70 million, representing 19–25% growth over 2025, reflecting NIRLAB integration.

  • Handheld product and service revenue expected to grow 18–21% year-over-year.

  • Adjusted gross margins projected in the mid to high 50% range for 2026, with a goal of 100 bps improvement.

  • Adjusted EBITDA loss expected to be in the mid-single-digit millions, with positive adjusted EBITDA targeted for 2027.

  • Recurring revenue expected to expand, with software, service, and support opportunities exceeding $10 million per year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more